Jasper Therapeutics Inc. (JSPR) Stock Price, Quote & News

Company Profile

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic sp...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 549 1400

Website: jaspertx.com

Address:

2200 Bridge Pkwy, Suite 102, Redwood City, United States

Mario19860 Feb. 4 at 4:16 PM

$JSPR again fall

0 · Reply

Goworklikedonkey Feb. 1 at 5:26 PM

$JSPR

0 · Reply

FIREINSP Jan. 30 at 3:01 PM

$JSPR sold it all for a nice loss. This is garbage,..

0 · Reply

sionist Jan. 25 at 3:44 AM

$BCAB @BiotechValues is a scammer. and cruse mania...Recntly he's luring individual investors in other stocks($JSPR $ARCV $NKTR). I know he's been reported to the SEC by someone. Pump & dump!

0 · Reply

OfficialStocktwitsUser Jan. 23 at 11:10 PM

$JSPR RSI: 38.05, MACD: -0.0746 Vol: 0.16, MA20: 1.68, MA50: 1.73 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

kellymone2 Jan. 22 at 12:16 PM

$JSPR long hold and SUPER

1 · Reply

kim14e Jan. 21 at 11:24 PM

$JSPR I’m out -26% This fucking fraud must be bankrupted and delisted in the world They don’t make medicine and only make fraud

0 · Reply

sionist Jan. 21 at 8:40 AM

[WARNING] Watch out for @BiotechValues . $JSPR $PEPG $ACRV $NKTX pump & dump!

1 · Reply

sionist Jan. 21 at 8:35 AM

The epcam data doesn't come out until at least May-June, even considering scan and readout times. The company may be delisted on Feb. 2 because it doesn't meet the minimum bidding requirements, or it may go bankrupt because it doesn't have the cash to run right away. There's no guarantee that the results are good because they weren't very satisfactory in the last scan. Scalability also seems to fall apart other than colorectal cancer. Beware of @biotechvalue instigating a buy with epcam data. He's a pump & dump. He's a vicious person who sells, telling investors to buy stocks.$BCAB He's done that many times before. $JSPR $ARCV

0 · Reply

fryfinancial Jan. 21 at 1:01 AM

$JSPR great opportunity to buy

0 · Reply

Jasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies in Chronic Urticaria Transcript

Jan 8, 2026, 7:00 AM EST - 27 days ago

Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

Jan 7, 2026, 4:30 PM EST - 27 days ago

Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth

Dec 2, 2025, 5:53 PM EST - 2 months ago

Jasper Therapeutics, Inc. (JSPR) Discusses Investigation Into BEACON Study Anomalies and Preliminary ETESIAN Asthma Data Transcript

Dec 2, 2025, 7:00 AM EST - 2 months ago

Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation

Dec 1, 2025, 4:30 PM EST - 2 months ago

Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation

Nov 22, 2025, 11:49 PM EST - 2 months ago

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Driven Brands and Jasper Therapeutics on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

DRVN

Nov 17, 2025, 12:13 PM EST - 2 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Nov 10, 2025, 6:53 PM EST - 3 months ago

JSPR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Nov 10, 2025, 8:00 AM EST - 3 months ago

Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 7, 2025, 9:52 AM EST - 3 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Nov 4, 2025, 8:00 AM EST - 3 months ago

Jasper Therapeutics to Present at Upcoming Investor Conferences

Oct 10, 2025, 8:05 PM EDT - 4 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Sep 22, 2025, 1:05 PM EDT - 4 months ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Jasper Therapeutics, Inc. (JSPR)

Sep 19, 2025, 12:07 AM EDT - 4 months ago

Jasper Therapeutics Announces Pricing of $30 Million Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

Sep 18, 2025, 4:08 PM EDT - 4 months ago

Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

Aug 13, 2025, 4:05 PM EDT - 6 months ago

Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 11, 2025, 12:18 PM EDT - 7 months ago

JSPR Investors Have Opportunity to Join Jasper Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Jul 9, 2025, 8:00 AM EDT - 7 months ago

Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway

Jul 7, 2025, 1:25 PM EDT - 7 months ago

Jasper Therapeutics Shares Fall On Briquilimab Drug Lot Problem

Jul 7, 2025, 7:30 AM EDT - 7 months ago

Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria

Jun 14, 2025, 10:00 AM EDT - 8 months ago

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Jun 3, 2025, 8:00 AM EDT - 8 months ago

Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress

May 12, 2025, 4:05 PM EDT - 9 months ago

Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Mar 1, 2025, 12:45 PM EST - 1 year ago

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 28, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Feb 27, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

Feb 25, 2025, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Present at Upcoming March Investor Conferences

Feb 10, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 4, 2025, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

Jan 8, 2025, 7:00 AM EST - 1 year ago

Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

Jan 6, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025

Dec 2, 2024, 4:30 PM EST - 1 year ago

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma

Nov 18, 2024, 10:09 AM EST - 1 year ago

Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma

Nov 13, 2024, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Participate at Upcoming Investor Conferences

Nov 7, 2024, 7:30 AM EST - 1 year ago

Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Oct 14, 2024, 9:22 AM EDT - 1 year ago

Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday?

Oct 14, 2024, 7:00 AM EDT - 1 year ago

Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Sep 10, 2024, 7:30 AM EDT - 1 year ago

Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma

Mario19860 Feb. 4 at 4:16 PM

$JSPR again fall

0 · Reply

Goworklikedonkey Feb. 1 at 5:26 PM

$JSPR

0 · Reply

FIREINSP Jan. 30 at 3:01 PM

$JSPR sold it all for a nice loss. This is garbage,..

0 · Reply

sionist Jan. 25 at 3:44 AM

$BCAB @BiotechValues is a scammer. and cruse mania...Recntly he's luring individual investors in other stocks($JSPR $ARCV $NKTR). I know he's been reported to the SEC by someone. Pump & dump!

0 · Reply

OfficialStocktwitsUser Jan. 23 at 11:10 PM

0 · Reply

kellymone2 Jan. 22 at 12:16 PM

$JSPR long hold and SUPER

1 · Reply

kim14e Jan. 21 at 11:24 PM

$JSPR I’m out -26% This fucking fraud must be bankrupted and delisted in the world They don’t make medicine and only make fraud

0 · Reply

sionist Jan. 21 at 8:40 AM

[WARNING] Watch out for @BiotechValues . $JSPR $PEPG $ACRV $NKTX pump & dump!

1 · Reply

sionist Jan. 21 at 8:35 AM

0 · Reply

fryfinancial Jan. 21 at 1:01 AM

$JSPR great opportunity to buy

0 · Reply

kellymone2 Jan. 20 at 3:52 PM

$JSPR we need volume

0 · Reply

biovaluable Jan. 19 at 11:56 AM

$BCAB $BCAB $JSPR disasters of @BiotechValues

0 · Reply

Mario19860 Jan. 19 at 11:41 AM

$JSPR this stock fail one year just fail an fail...

0 · Reply

sionist Jan. 17 at 9:46 AM

$BCAB Who inciting buying with pump & dump and selling stock behind the scenes has started agitating again. Be careful. @biotechvalues is a vicious agitator. This guy recommended Stock Has All Been Undergoing A Large Fall Recently. $BCAB $JSPR $ACRV

1 · Reply

sionist Jan. 16 at 1:42 AM

$BCAB At first I thought @Sdbiotechinvestor was a bad guy and a short seller. But he was an honest and cool-headed investor. He kept me from losing money because of @biotechvalue and warned me as much as he could. Thanks to him. Most of the stocks that $JSPR $BCAB $ACRV @biotechvalue pumped on Twitter and here went to hell. They only make money when they get away from where @biotechvalue invests. They say they went on a cruise, but they don't know where they're stuck in their room

1 · Reply

sionist Jan. 15 at 11:14 PM

$BCAB evidence2 $JSPR

0 · Reply

sionist Jan. 15 at 11:13 PM

$BCAB @biotechvalue Will he do the same in $BCAB what he did in $JSPR?

0 · Reply

sionist Jan. 15 at 11:00 PM

I've lost two big bucks this year because of @BiotechValues. $JSPR biotechvalue is a demon that promoted jspr a lot, and then bragged about his bottom line, saying that he sold it out before that when he had a data problem in July last year. So did $BCAB this time. He encouraged buying and sold the stock in the background. He promoted the purchase earlier and said on the phone that he had already sold it.I know he was reported to the SEC by @SDBiotechInvestor. If you buy the stock he recommended, you get hell. Now that I think about it, it could be a short position.

0 · Reply

VincentGogh Jan. 15 at 8:32 PM

$JSPR Any thoughts on a buyout target 🤔... wouldn't take much and maybe a win for both if the offer was good 🤷🏼‍♂️

1 · Reply

Biotech41 Jan. 15 at 3:02 PM

$JSPR What now?

1 · Reply

Mario19860 Jan. 14 at 8:18 PM

$JSPR

2 · Reply

MikiTrader Jan. 13 at 8:43 PM

$JSPR Bottom line, I didn’t buy it

0 · Reply

Market Cap	41.42M
Revenue (ttm)	0.00
Net Income (ttm)	-71.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	264,800
Avg Vol	2,066,004
Day's Range	N/A - N/A
Shares Out	27.98M
Stochastic %K	12%
Beta	3.07
Analysts	Strong Sell
Price Target	$12.67